Your institution may have access to this item. Find your institution then sign in to continue.
Title
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Authors
Medley, L; Morel, A N; Farrugia, D; Reed, N; Hayward, N; Davies, J M; Kirichek, O; Thakker, R V; Talbot, D C
Abstract
This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
Publication
British journal of cancer, 2011, Vol 104, Issue 7, p1067